1. Market Research
  2. > Pharmaceutical
  3. > Drug Development Market Trends
Age-Related Macular Degeneration: Competitive Landscape to 2026

Age-Related Macular Degeneration: Competitive Landscape to 2026

  • December 2018
  • 153 pages
  • ID: 5727685
  • Format: PDF
  • By GlobalData

Summary

Table of Contents

Search Inside

Age-Related Macular Degeneration: Competitive Landscape to 2026

Summary
The Age-Related Macular Degeneration (AMD) market has been dominated by big pharma companies and their pipeline candidates are ensuring a share of this lucrative market, in spite of patent expiries of their highly-priced products.

Age-Related macular degeneration (AMD) is one of the leading cause of vision loss among people ages 50 and over in the developed world, characterized by the deterioration or breakdown of the macula, a small area of the central retina needed for sharp central vision, gradually diminishing central vision as a result in one or both eyes.

In recent years Regeneron and Bayer became top sellers in the AMD space with their anti-VEGF, Eylea. While both Bayer and Regeneron are among the top seven industry sponsors of clinical trials in AMD, neither of these companies have an AMD drug in late stages of development (Phase IIb/ Phase III) and it is expected that they will not launch a new product by 2026.

However, Novartis is planning to launch its new anti-VEGF, brolucizumab in 2019, while Roche will compensate for its loss through the launch of faricimab, first-in-class bispecific antibody in 2024 designed for the treatment of wet AMD.The current AMD market is rather sparse, comprising of only five available drugs in the US, 5EU, and Japan and four in China.

One of the marketed anti-VEGFs, Roche’s Avastin (bevacizumab), is used off-label for wet AMD, mainly due to its vastly lower price-tag.

The other form of the late stage of AMD is a dry or athropic form, called geographic atrophy (GA), for which no effective treatments are available, and therefore these patients remain underserved. The AMD pipeline is strong although the attrition rate is high, particularly in dry AMD, for which all drugs have failed at the clinical stage of development.

Out of the eleven drugs in late-stage clinical development, only two are being developed for the treatment of GA: Apellis’ APL-2, and Ophthotech’s Zimura. The majority, about 70% of the drugs in clinical stages of development, are designed to treat wet AMD, which leaves plenty of opportunities for developers to come up with effective treatments against GA.

According to the report "Age-Related Macular Degeneration: Competitive Landscape to 2026", the AMD pipeline consists of 236 drugs spanning all stages of development. Drugs inhibiting angiogenesis remain the major focus of drug developers for wet AMD as they account for close to 40% of the pipeline.

This report provides an assessment of the pipeline, clinical, and commercial landscape of AMD.Overall, it is expected that the approval of new vascular endothelial growth factor (VEGF) inhibitors with longer efficacy duration will drive AMD market growth during the next decade; however, launching anti-VEGF biosimilars, particularly of ranibizumab, and the continued pressure from payers mandating the use of the vastly cheaper Avastin for wet AMD will curb the uptake of new anti-VEGF therapies.

Additionally, two anti-complement agents for the treatment of GA will drive an increase in treated AMD cases, profoundly expanding the overall AMD market.

Scope
- Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type
- Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
- Commercial Assessment: leading marketed products, current and future players
- Competitive Landscape Analysis: key market events (2016-2026).

Reasons to buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global AMD market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AMD market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
25% Off

($3495)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Vascular Endothelial Growth Factor B - Pipeline Review, H1 2020

Vascular Endothelial Growth Factor B - Pipeline Review, H1 2020

  • $ 3500
  • January 2020

Vascular Endothelial Growth Factor B - Pipeline Review, H1 2020SummaryVascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Vascular endothelial growth factor B also known as VEGF-B is ...

Intraocular Lens (IOL) - Medical Devices Pipeline Assessment, 2019

Intraocular Lens (IOL) - Medical Devices Pipeline Assessment, 2019

  • $ 4000
  • December 2019

Intraocular Lens (IOL) - Medical Devices Pipeline Assessment, 2019SummaryMedical Devices sector report, “Intraocular Lens (IOL) - Medical Devices Pipeline Assessment, 2019" provides an overview of Intraocula ...

Cholelithiasis Global Clinical Trials Review, H1, 2020

Cholelithiasis Global Clinical Trials Review, H1, 2020

  • $ 2500
  • January 2020

Cholelithiasis Global Clinical Trials Review, H1, 2020Summaryclinical trial report, “Cholelithiasis Global Clinical Trials Review, H1, 2020" provides an overview of Cholelithiasis Clinical trials scenario.This ...


ref:plp2018

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on